Logo image of HBMD

Howard Bancorp Inc (HBMD) Stock Fundamental Analysis

NASDAQ:HBMD - Nasdaq - Common Stock

23.3  -0.49 (-2.06%)

After market: 23.3 0 (0%)

Fundamental Rating

2

Overall HBMD gets a fundamental rating of 2 out of 10. We evaluated HBMD against 405 industry peers in the Banks industry. HBMD may be in some trouble as it scores bad on both profitability and health. HBMD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HBMD was profitable.
HBMD Yearly Net Income VS EBIT VS OCF VS FCFHBMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 20M 40M 60M

1.2 Ratios

Industry RankSector Rank
ROA 0.97%
ROE 7.95%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HBMD Yearly ROA, ROE, ROICHBMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 2 -2 4 -4 6

1.3 Margins

The Operating Margin and Gross Margin are not available for HBMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 27.8%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HBMD Yearly Profit, Operating, Gross MarginsHBMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 10 -10

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for HBMD has been reduced compared to 1 year ago.
HBMD has a better debt/assets ratio than last year.
HBMD Yearly Shares OutstandingHBMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 5M 10M 15M
HBMD Yearly Total Debt VS Total AssetsHBMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 500M 1B 1.5B 2B 2.5B

2.2 Solvency

A Debt/Equity ratio of 0.09 indicates that HBMD is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
HBMD Yearly LT Debt VS Equity VS FCFHBMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 100M 200M 300M

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 257.83% over the past year.
Looking at the last year, HBMD shows a small growth in Revenue. The Revenue has grown by 1.19% in the last year.
Measured over the past years, HBMD shows a quite strong growth in Revenue. The Revenue has been growing by 15.28% on average per year.
EPS 1Y (TTM)257.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)1.19%
Revenue growth 3Y14.42%
Revenue growth 5Y15.28%
Sales Q2Q%8.21%

3.2 Future

The Earnings Per Share is expected to grow by 24.47% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 1.68% on average over the next years.
EPS Next Y258.67%
EPS Next 2Y78.61%
EPS Next 3Y48.07%
EPS Next 5Y24.47%
Revenue Next Year11.11%
Revenue Next 2Y2.55%
Revenue Next 3Y3.49%
Revenue Next 5Y1.68%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HBMD Yearly Revenue VS EstimatesHBMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
HBMD Yearly EPS VS EstimatesHBMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 0.5 -0.5 1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 17.79, the valuation of HBMD can be described as rather expensive.
HBMD is valuated rather cheaply when we compare the Price/Earnings ratio to 29.62, which is the current average of the S&P500 Index.
HBMD is valuated rather expensively with a Price/Forward Earnings ratio of 21.76.
When comparing the Price/Forward Earnings ratio of HBMD to the average of the S&P500 Index (22.70), we can say HBMD is valued inline with the index average.
Industry RankSector Rank
PE 17.79
Fwd PE 21.76
HBMD Price Earnings VS Forward Price EarningsHBMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HBMD Per share dataHBMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HBMD's earnings are expected to grow with 48.07% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y78.61%
EPS Next 3Y48.07%

More info and screens

0

5. Dividend

5.1 Amount

HBMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Howard Bancorp Inc

NASDAQ:HBMD (1/21/2022, 8:04:49 PM)

After market: 23.3 0 (0%)

23.3

-0.49 (-2.06%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners11.45%
Ins Owner Change0%
Market Cap438.27M
Analysts80
Price Target24.48 (5.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 17.79
Fwd PE 21.76
P/S 4.98
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB N/A
EV/EBITDA N/A
EPS(TTM)1.31
EY5.62%
EPS(NY)1.07
Fwd EY4.6%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4.68
BVpS16.38
TBVpSN/A
PEG (NY)0.07
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.97%
ROE 7.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 27.8%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)257.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y258.67%
EPS Next 2Y78.61%
EPS Next 3Y48.07%
EPS Next 5Y24.47%
Revenue 1Y (TTM)1.19%
Revenue growth 3Y14.42%
Revenue growth 5Y15.28%
Sales Q2Q%8.21%
Revenue Next Year11.11%
Revenue Next 2Y2.55%
Revenue Next 3Y3.49%
Revenue Next 5Y1.68%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A